Department of Pharmacology, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-ku, Tokyo 101-8310, Japan.
Neuropharmacology. 2012 Feb;62(2):907-13. doi: 10.1016/j.neuropharm.2011.09.021. Epub 2011 Sep 28.
GABA released from accumbal GABAergic interneurons plays an inhibitory role in the regulation of dopamine efflux through GABA(B) and GABA(A) receptors located on accumbal dopaminergic nerve endings. The cytosolic newly synthesised GABA alters vesicular GABA levels and, accordingly, the amount of GABA released from the neuron. Therefore, we hypothesised that glutamic acid decarboxylase (GAD) which generates GABA in accumbal GABAergic neurons, at least partly determines the GABA receptor subtype-mediated GABAergic tonus. To (in)validate this hypothesis, in vivo microdialysis was used to study the effects of an intra-accumbal infusion of the GAD inhibitor l-allylglycine (allylglycine) on the accumbal dopamine efflux of freely moving rats. The intra-accumbal infusion of allylglycine (50.0, 250.0 and 500.0 nmol) dose-dependently increased the accumbal dopamine levels. The co-administration of tetrodotoxin (720 pmol) suppressed the allylglycine (500.0 nmol)-induced dopamine efflux. The intra-accumbal infusion of GABA(B) receptor agonist baclofen (2.5 and 5.0 nmol) inhibited the allylglycine (500.0 nmol)-induced dopamine efflux. The baclofen's effects were counteracted by GABA(B) receptor antagonist saclofen (10.0 nmol). Neither GABA(A) receptor agonist (muscimol: 25.0 and 250.0 pmol) nor antagonist (bicuculline: 50.0 pmol) altered the allylglycine (250.0 and 500.0 nmol)-induced dopamine efflux. The present study provides in vivo neurochemical evidence that newly synthesised GABA that exerts an inhibitory tonus on the accumbal dopaminergic activity, acts at the level of GABA(B) receptors, but not GABA(A) receptors. The present study also shows that there is an allylglycine-insensitive GABA pool that release GABA exerting an inhibitory control of the accumbal dopaminergic activity, at the level of GABA(A) receptors. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.
从伏隔核 GABA 能中间神经元释放的 GABA 通过位于伏隔核多巴胺神经末梢上的 GABA(B)和 GABA(A)受体发挥抑制作用,调节多巴胺的外排。细胞溶质中新合成的 GABA 改变囊泡 GABA 水平,相应地,神经元释放的 GABA 量也发生改变。因此,我们假设,在伏隔核 GABA 能神经元中产生 GABA 的谷氨酸脱羧酶(GAD)至少部分决定了 GABA 受体亚型介导的 GABA 能紧张度。为了(不)验证这一假设,我们使用体内微透析技术研究了伏隔核内灌流 GABA 抑制剂 L-allylglycine(allylglycine)对自由活动大鼠伏隔核多巴胺外排的影响。伏隔核内灌流 allylglycine(50.0、250.0 和 500.0 nmol)剂量依赖性地增加了伏隔核多巴胺水平。共同给予河豚毒素(720 pmol)抑制了 allylglycine(500.0 nmol)引起的多巴胺外排。伏隔核内灌流 GABA(B)受体激动剂 baclofen(2.5 和 5.0 nmol)抑制了 allylglycine(500.0 nmol)引起的多巴胺外排。Baclofen 的作用被 GABA(B)受体拮抗剂 saclofen(10.0 nmol)抵消。GABA(A)受体激动剂(muscimol:25.0 和 250.0 pmol)或拮抗剂(bicuculline:50.0 pmol)均未改变 allylglycine(250.0 和 500.0 nmol)引起的多巴胺外排。本研究提供了体内神经化学证据,表明发挥抑制伏隔核多巴胺活性紧张作用的新合成 GABA 作用于 GABA(B)受体水平,而不是 GABA(A)受体水平。本研究还表明,存在一种 allylglycine 不敏感的 GABA 池,该 GABA 池释放 GABA,对伏隔核多巴胺活性发挥抑制控制作用,作用于 GABA(A)受体水平。本文是特刊“创伤后应激障碍”的一部分。